Tarsus: TP-03 Phase 2a Clinical Trial Shows Positive Data In MGD In Patients With Demodex Mites

Tarsus Pharmaceuticals, Inc. (TARS) announced Monday positive topline results from the Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.

Related Keywords

,Bobak Azamian ,Tarsus Pharmaceuticals Inc ,Drug Administration ,More Such Health News ,Tarsus Pharmaceuticals ,Ersa Phase ,Meibomian Gland Disease ,Meibomian Gland Secretion Score ,Chief Executive Officer ,Tarsus ,Ep 03 ,Eibomian Gland Disease ,Demodex Mites ,Lotilaner ,